Here, we determined the physiologic and clinical relevance of CCL2/CCR2 signaling proteins to DCIS progression using a combination of patient tissues, PDX models and immortalized breast epithelial cells. This evidence concerns the gene CCR2 and ductal breast carcinoma in situ.